Endocrine

Diabetic foot care and ulcer management

Clinical Overview and When to Suspect Diabetic Foot Ulcer

— Lifetime risk in diabetics: 19–34%; recurrence after healing approaches 40% at 1 year, 65% at 5 years.

— Precedes ~85% of diabetes-related lower-extremity amputations.

— 5-year mortality after a new ulcer (~30%) rivals many cancers.

— Peripheral neuropathy → loss of protective sensation, motor imbalance (claw toes, prominent metatarsal heads), autonomic dryness/fissuring.

— Peripheral artery disease (PAD) → impaired perfusion and healing; present in ~50% of foot ulcers.

— Mechanical trauma/deformity → ill-fitting shoes, callus, Charcot deformity, foreign body.

— Every diabetic visit: ask about foot pain, numbness, prior ulcer, footwear; inspect both feet at least annually (ADA Standards of Care) and at every visit if high-risk.

— Red flags in primary care: new callus, drainage staining the sock, unilateral foot swelling or warmth, new toe deformity, "my shoe feels different."

— Painless wound + intact-appearing skin around it strongly suggests neuropathic etiology; rest pain or night pain suggests ischemia.

— 0: no neuropathy → annual screen.

— 1: neuropathy → every 6–12 months.

— 2: neuropathy + PAD or deformity → every 3–6 months.

— 3: prior ulcer/amputation or ESRD → every 1–3 months, podiatry co-management.

Board pearl: A diabetic patient who cannot feel the 10-g Semmes-Weinstein monofilament at any of the standard plantar sites has lost protective sensation and is automatically at elevated ulcer risk — document and arrange protective footwear referral the same visit.

Definition: Full-thickness skin break distal to the malleoli in a patient with diabetes, typically arising from the interaction of neuropathy, ischemia, and unrecognized repetitive trauma.

Epidemiology:

Pathophysiologic triad (always look for all three):

When to suspect / actively look:

Risk stratification (IWGDF categories):

Presentation Patterns and Key History

— Neuropathic ("mal perforans"): painless, punched-out, surrounded by thick callus, located over plantar pressure points (1st/5th metatarsal heads, great toe, heel). Warm foot, bounding pulses, dry skin.

— Ischemic: painful (especially at rest or with elevation), located on toe tips, lateral 5th metatarsal, or heel, dry necrotic base, atrophic shiny skin, absent pulses, dependent rubor.

— Neuroischemic (most common, ~50%): mixed features; pain may be blunted by neuropathy even when perfusion is poor — do not be reassured by absence of pain.

— Wound timeline: onset, inciting event (new shoes, pedicure, walking barefoot, foreign body), prior episodes at the same site.

— Glycemic control: recent A1c, hypoglycemia, medication adherence.

— Vascular symptoms: claudication distance, rest pain, prior revascularization.

— Neuropathic symptoms: burning, numbness, "walking on cotton."

— Systemic signs of infection: fevers, chills, worsening hyperglycemia, new insulin requirement — often the first clue to deep infection.

— Functional/social: smoking, alcohol, vision (can the patient see their feet?), can they reach their feet, home support, footwear, occupation, prior amputations.

— Comorbidities driving healing failure: CKD/dialysis, heart failure, malnutrition (albumin), immunosuppression, depression.

Key distinction: Claudication that improves with standing still suggests vascular disease; "claudication" that improves only with sitting/leaning forward is pseudoclaudication from lumbar stenosis — a common Step 3 distractor in older diabetics with foot pain.

Three archetypal ulcer phenotypes — recognize them on the stem:

History to extract every time:

CCS pearl: When a diabetic presents with unexplained hyperglycemia or new DKA, always inspect the feet before closing the encounter — an occult infected ulcer is a classic destabilizer and a frequent missed-diagnosis item.

Physical Exam Findings and Hemodynamic Assessment

— Skin: callus, fissures, maceration, tinea, nail dystrophy, hair loss, dependent rubor, pallor on elevation.

— Deformity: claw/hammer toes, hallux valgus, prominent metatarsal heads, rocker-bottom Charcot foot.

— Wound: location, size (length × width × depth), base (granulation vs slough vs eschar vs exposed tendon/bone), edges (undermined, rolled), surrounding erythema, drainage, odor.

— 10-g Semmes-Weinstein monofilament at ≥4 plantar sites (hallux, 1st/3rd/5th metatarsal heads). Inability to feel = loss of protective sensation.

— 128-Hz tuning fork at the hallux IP joint; absent vibration is highly predictive of neuropathy.

— Ankle reflexes, proprioception, pinprick.

— Palpate DP and PT pulses bilaterally; auscultate femorals for bruits.

— Capillary refill, temperature gradient, Buerger test (pallor on elevation, rubor on dependency).

— Ankle-brachial index (ABI):

— Normal 1.0–1.4; ≤0.90 = PAD; <0.40 = severe ischemia.

— >1.30 = noncompressible (medial calcinosis) — common in diabetes/ESRD; obtain toe-brachial index (TBI <0.70 abnormal) or transcutaneous oximetry (TcPO₂) instead.

Board pearl: A warm, swollen, erythematous, painless foot without an ulcer in a neuropathic diabetic = acute Charcot neuroarthropathy until proven otherwise — total contact cast and offload immediately; misdiagnosing as cellulitis is a classic stem trap.

Inspection (shoes and socks off, both feet, between every toe):

Neurologic exam:

Vascular/hemodynamic exam:

"Probe-to-bone" test: sterile blunt probe at ulcer base striking firm, gritty bone → PPV for osteomyelitis ~60%, NPV ~90% in outpatient settings; combine with imaging/labs.

Wagner classification (rapid grading): 0 intact at-risk foot, 1 superficial, 2 deep to tendon/capsule, 3 deep with abscess/osteo, 4 forefoot gangrene, 5 whole-foot gangrene.

Diagnostic Workup — Initial Labs, Imaging, and Bedside Studies

— CBC with differential (leukocytosis often blunted in diabetes; absence does not rule out infection).

— ESR and CRP: ESR >70 mm/hr raises suspicion for osteomyelitis (LR ~11); trend CRP to monitor response.

— BMP, creatinine, eGFR: baseline before contrast imaging, antibiotic dosing.

— A1c and fingerstick glucose: acute hyperglycemia often heralds infection.

— Blood cultures × 2 only if systemic signs (fever, hypotension, leukocytosis).

— Wound cultures: obtain after debridement from deep tissue or curettage, not superficial swab (skin flora contamination). Swabs are last resort.

— Plain film of the foot (3 views) for every new ulcer: look for soft-tissue gas, foreign body, cortical erosion, periosteal reaction, osteolysis.

— Bony changes of osteomyelitis lag clinical infection by 2 weeks; a negative film does not exclude it — repeat in 2–4 weeks or escalate imaging.

— ABI ± toe pressures/TBI, segmental pressures, pulse-volume recordings.

— TcPO₂ <30 mm Hg predicts poor wound healing.

Step 3 management: For a new diabetic foot ulcer in clinic, the minimum same-day workup is: wound measurement + photograph, monofilament/vibration testing, pedal pulses + ABI, plain foot radiograph, CBC/CRP/ESR/BMP/A1c, and deep wound culture after sharp debridement — then decide on outpatient vs admission based on severity and perfusion.

Indicated when ulcer is present or infection suspected — outpatient/ED bundle:

Imaging — start with plain radiographs:

Vascular bedside studies:

Glycemic and metabolic stabilization labs: venous bicarbonate or VBG, lactate, anion gap if ill-appearing — diabetic foot infection is a classic DKA/HHS precipitant.

Diagnostic Workup — Advanced and Confirmatory Studies

— Sensitivity ~90%, specificity ~80%; identifies abscess, sinus tracts, and extent for surgical planning.

— Findings: low T1 marrow signal, high T2/STIR, post-contrast enhancement.

— Limitations: hardware artifact, ESRD (gadolinium/NSF risk — use eGFR <30 caution, prefer macrocyclic agents).

— Tagged WBC scan + sulfur colloid marrow scan (helpful in postoperative bone).

— CT for surgical planning, gas in deep planes; less sensitive than MRI for marrow.

— PET/CT in selected refractory cases.

— Percutaneous or intraoperative bone sample for histology + culture, ideally after 2-week antibiotic holiday if clinically safe, to guide targeted long-course therapy.

— Indications: diagnostic uncertainty, failed empiric therapy, multidrug-resistant risk, planned long IV course.

— Arterial duplex ultrasound first-line noninvasive.

— CT angiography or MR angiography for anatomic mapping (caution with contrast in CKD).

— Digital subtraction angiography (DSA) when revascularization is planned — diagnostic and therapeutic in the same session.

— EMG/NCS if atypical (asymmetric, motor-predominant, rapid progression) to exclude CIDP, vasculitic neuropathy, B12 deficiency, alcohol, uremia.

Board pearl: Suspect osteomyelitis when an ulcer is >2 cm², deeper than 3 mm, or persists >6 weeks despite appropriate care, or when probe-to-bone is positive with ESR >70 — proceed to MRI and consider bone biopsy before committing to a 6-week antibiotic course.

MRI of the foot (without and with gadolinium) — test of choice for osteomyelitis:

Alternatives when MRI contraindicated:

Bone biopsy = gold standard for osteomyelitis:

Vascular confirmatory studies (when ABI/TBI abnormal or healing fails at 4 weeks):

Neuropathy confirmation (rarely needed for typical cases):

Nutritional/metabolic adjuncts for non-healing wounds: prealbumin, albumin, vitamin D, zinc, B12, TSH.

Risk Stratification and First-Line Management Logic

— Uninfected: no purulence, no inflammation → outpatient wound care, no antibiotics.

— Mild: local infection, erythema ≤2 cm around ulcer, skin/subcutaneous only → outpatient oral antibiotics.

— Moderate: erythema >2 cm, deep structures involved (fascia, tendon, bone, joint), no SIRS → admit vs close outpatient follow-up; often IV antibiotics.

— Severe: SIRS/sepsis, hemodynamic instability, metabolic derangement (DKA), critical ischemia → admit, broad-spectrum IV antibiotics, urgent surgical and vascular consults.

— Sharp debridement of callus, slough, and nonviable tissue at each visit.

— Sepsis/infection control — appropriate antibiotics, drainage of abscess.

— Supply (perfusion) — assess and restore arterial flow if PAD.

— Shoes/offloading — total contact cast (TCC) is gold standard for plantar neuropathic ulcers; removable cast walker if TCC contraindicated.

— Sugars — A1c target individualized (typically <7–8%); avoid hypoglycemia.

— Tissue debridement, Inflammation/infection control, Moisture balance (moist but not macerated), Edge advancement.

— Dry wound → hydrogel; moderate exudate → foam/alginate; heavy exudate/infected → alginate + antimicrobial (silver, iodine cadexomer); avoid occlusive dressings on infected/ischemic wounds.

Step 3 management: A plantar neuropathic ulcer that is clean, perfused, and uninfected → debride, apply total contact cast, recheck in 1 week, no antibiotics. Adding antibiotics to a non-infected ulcer is a classic wrong-answer choice.

Classify infection severity (IDSA/IWGDF) — drives disposition:

Foundational therapy pillars (the "5 S's" — apply to every ulcer):

Wound bed preparation (TIME framework):

Dressing choice by exudate:

Healing benchmark: ≥50% reduction in wound area by 4 weeks predicts healing by 12 weeks; failure to meet this is a trigger to reassess perfusion, infection, offloading, and adherence.

Pharmacotherapy — First-Line Antibiotic Regimens

— Target: streptococci and MSSA (acute) or polymicrobial (chronic).

— Cephalexin 500 mg PO QID, dicloxacillin, or amoxicillin-clavulanate 875/125 mg BID.

— Penicillin-allergic: clindamycin 300–450 mg PO QID or levofloxacin + clindamycin.

— Ampicillin-sulbactam 3 g IV q6h, ertapenem 1 g IV daily, or ceftriaxone + metronidazole.

— Chronic wound or prior antibiotics → expand for gram-negatives and anaerobes: piperacillin-tazobactam 4.5 g IV q6h or ertapenem.

— Add vancomycin or linezolid or daptomycin for MRSA coverage when indicated.

— Vancomycin + piperacillin-tazobactam (or meropenem if ESBL risk).

— Add clindamycin if necrotizing infection suspected (antitoxin effect).

Board pearl: Do not culture or treat an uninfected chronic ulcer — empiric antibiotics select resistance and mask underlying ischemia or osteomyelitis, the actual reason it isn't healing.

Principle: Antibiotics treat infection, not colonization. All open ulcers grow bacteria — treat only when clinical signs of infection are present.

Mild infection (oral, 1–2 weeks), no recent antibiotics or MRSA risk:

MRSA risk (prior MRSA, recent hospitalization, high local prevalence, IVDU): add or substitute doxycycline 100 mg BID, TMP-SMX DS BID, or linezolid.

Moderate infection (often IV initially, 2–3 weeks):

Severe infection / sepsis (broad empiric, then de-escalate):

Pseudomonas coverage (warm climate, water exposure, macerated wound, failed prior therapy): pip-tazo, cefepime, or meropenem.

Osteomyelitis: culture-directed therapy for 6 weeks (IV or highly bioavailable oral such as fluoroquinolone + rifampin for staph); shorter (≤1 week) if all infected bone resected with clean margins.

Duration rules of thumb: soft-tissue mild 1–2 wk, moderate 1–3 wk, severe 2–4 wk, osteomyelitis 6 wk (or 3 mo if hardware retained).

Procedures — Debridement, Offloading, Revascularization, and Adjuncts

— Performed at bedside or OR; removes callus, slough, biofilm, and nonviable tissue down to bleeding viable tissue.

— Repeat at each visit ("maintenance debridement") — accelerates healing more than any topical agent.

— Avoid aggressive debridement in ischemic wounds without revascularization (risk of larger non-healing defect); use conservative/enzymatic instead.

— Total contact cast = gold standard (healing rates 70–90% by 12 weeks).

— Irremovable knee-high cast walker (next best — removes adherence problem).

— Removable cast walker, surgical shoes, felted foam — progressively less effective.

— Contraindications to TCC: active infection, significant ischemia (ABI <0.5), heavy exudate, deep ulcer with sinus.

— Endovascular (angioplasty ± stent) preferred for focal lesions, high surgical risk, or tibial disease — shorter recovery, repeatable.

— Open bypass (e.g., femoral-popliteal/tibial with vein conduit) for long-segment disease and good surgical candidates with adequate vein — BEST-CLI trial: bypass with great saphenous vein superior for chronic limb-threatening ischemia in suitable candidates.

— Negative-pressure wound therapy (NPWT) for large, deep, post-debridement or post-amputation wounds.

— Bioengineered skin substitutes (e.g., Apligraf, Dermagraft) and platelet-derived growth factor (becaplermin) for refractory neuropathic ulcers.

— Hyperbaric oxygen — selected Wagner ≥3 ulcers with adequate perfusion that have failed standard care.

CCS pearl: In severe diabetic foot infection, order urgent surgical consult for source control in parallel with antibiotics — drainage/debridement is the definitive therapy; antibiotics alone for a foot abscess is a wrong-move trap.

Sharp surgical debridement (cornerstone):

Offloading hierarchy (plantar neuropathic ulcers):

Revascularization (refer to vascular surgery early if ABI <0.8, TBI <0.7, TcPO₂ <30, or failed healing at 4 weeks):

Adjunctive therapies (after fundamentals optimized):

Amputation: indicated for uncontrolled infection, unreconstructable ischemia with gangrene, intractable pain, or non-functional limb.

Special Populations — Elderly and Renal/Hepatic Impairment

— Higher rates of PAD, malnutrition, frailty, dementia, vision loss — all impair self-inspection and adherence.

— Falls risk with TCC and offloading devices: gait assessment, walker/cane, physical therapy referral.

— Polypharmacy: avoid drug-drug interactions (warfarin + TMP-SMX, fluoroquinolones + QT-prolonging drugs).

— Realistic glycemic targets: A1c 7.5–8.0% in functionally limited elderly to minimize hypoglycemia; <8.5% in frail/limited life expectancy.

— Caregiver education is often more impactful than patient education — engage family at first visit.

— Markedly higher ulcer and amputation risk; calciphylaxis can mimic ischemic ulcer in dialysis patients (painful, necrotic, livedo).

— ABIs unreliable (medial calcinosis) → use TBI, TcPO₂, or duplex.

— Contrast cautions: iodinated contrast → pre-/post-hydration; gadolinium: avoid in eGFR <30 if possible, use macrocyclic agents (NSF risk historically with linear agents).

— Antibiotic dosing adjustments:

— Vancomycin — trough/AUC guided.

— Pip-tazo, cefepime, meropenem — renally dosed; cefepime neurotoxicity (encephalopathy, myoclonus) common in CKD.

— Fluoroquinolones, TMP-SMX, linezolid require renal/hematologic monitoring.

— Avoid nitrofurantoin (not a foot drug anyway), use caution with aminoglycosides.

— Avoid/limit tetracyclines, high-dose acetaminophen, rifampin, isoniazid analogs; monitor LFTs on prolonged therapy.

— Albumin <3 g/dL predicts poor healing — refer to nutrition.

Step 3 management: In an ESRD patient with a foot ulcer and ABI 1.4, do not be falsely reassured — order a toe-brachial index or TcPO₂ before deciding the wound is "well-perfused" and committing to a treatment plan that assumes intact arterial flow.

Elderly considerations:

CKD/ESRD:

Hepatic impairment:

Special Populations — Pregnancy, Pediatrics, and Other Subgroups

— Diabetic foot ulcers are uncommon (younger cohort) but seen in pregestational type 1 or long-standing type 2 diabetes.

— Safe antibiotics: penicillins, cephalosporins, clindamycin, vancomycin, azithromycin.

— Avoid: fluoroquinolones (cartilage), tetracyclines (teeth/bone after 2nd trimester), TMP-SMX (1st trimester — folate antagonism; 3rd trimester — kernicterus), aminoglycosides (ototoxicity).

— Imaging: prefer MRI without gadolinium; plain films acceptable with abdominal shielding.

— Tight glycemic control (fasting <95, 1-hr postprandial <140) improves healing and fetal outcomes.

— Ulcers rare; when present, screen for neuropathy, retinopathy, nephropathy simultaneously (microvascular co-clustering).

— Address footwear, athletic activity, body image around offloading devices, mental health.

— Highest-risk group — annual amputation rate ~10% on the contralateral side.

— Mandatory: custom-molded therapeutic shoes and inserts (Medicare covers annually for qualifying diabetics — the "Therapeutic Shoe Bill"), podiatry every 1–3 months, prosthetics/orthotics follow-up.

— Acute phase: warm, swollen, red foot ± deformity, often misdiagnosed as cellulitis or DVT.

— Diagnosis: clinical + plain films (early may be normal) + MRI (bone marrow edema, fractures, dislocation).

— Treatment: immediate offloading with TCC for 3–6+ months until temperature differential <2°C vs contralateral foot; then custom bracing (CROW boot).

Board pearl: A diabetic with a warm, swollen, painless red foot, no ulcer, normal WBC, and normal X-ray = acute Charcot — offload now; antibiotics are the wrong answer.

Pregnancy:

Pediatric/adolescent type 1 diabetes:

Patients with prior amputation:

Charcot neuroarthropathy:

Homeless or food-insecure patients: address shelter (cannot offload without a safe place to stay off the foot), nutrition, refrigeration for insulin.

Complications and Adverse Outcomes

— Cellulitis progressing to abscess (look for fluctuance, undermined edges) → requires I&D.

— Osteomyelitis — chronic, recurrent, often subclinical; underlies ~20% of moderate and 50–60% of severe diabetic foot infections.

— Septic arthritis of MTP or IP joints — joint warmth, effusion, restricted ROM.

— Necrotizing fasciitis / gas gangrene — pain out of proportion, crepitus, soft-tissue gas on imaging, rapid progression → surgical emergency.

— Tendon rupture (especially Achilles in poorly offloaded heel ulcers).

— Chronic limb-threatening ischemia (CLTI): rest pain ≥2 weeks, non-healing ulcer, or gangrene with PAD → urgent vascular evaluation; 1-year amputation risk 15–20% if untreated.

— Major amputation (above-ankle): ~50% 5-year mortality, comparable to advanced cancer; contralateral amputation within 5 years ~50%.

— Minor amputation (toe, ray, transmetatarsal): high re-ulceration rate; biomechanical changes drive new pressure points.

— Sepsis and septic shock — diabetes blunts febrile and leukocyte response; suspect with new hyperglycemia, tachycardia, AMS.

— DKA/HHS precipitated by infection.

— Acute kidney injury from sepsis, contrast, nephrotoxic antibiotics (aminoglycosides, vancomycin).

— C. difficile from prolonged broad-spectrum antibiotics.

— Drug toxicities: vancomycin nephrotoxicity, linezolid thrombocytopenia/serotonin syndrome, fluoroquinolone tendinopathy and QT prolongation.

Key distinction: Sudden severe pain in a previously painless neuropathic ulcer suggests a new process — deep abscess, necrotizing infection, or acute ischemia — and warrants emergent imaging and surgical evaluation, not reassurance.

Local complications:

Limb-threatening complications:

Systemic complications:

Psychosocial: depression, social isolation, loss of employment and mobility, caregiver burden.

Recurrence: 40% within 1 year, 65% within 5 years — frame ulcer healing as "diabetic foot in remission," not cured.

When to Escalate Care — ICU, Consult, and Inpatient Triage

— Moderate or severe infection (IDSA criteria).

— Systemic signs: fever, tachycardia, hypotension, AMS.

— Inability to take oral antibiotics or tolerate outpatient care.

— Need for IV antibiotics, urgent surgical debridement, or revascularization.

— Critical limb ischemia (rest pain, gangrene).

— Metabolic decompensation (DKA, HHS, AKI).

— Failed outpatient therapy at 48–72 hours.

— Social drivers: inability to offload, no caregiver, homelessness, nonadherence with high stakes.

— Septic shock requiring vasopressors.

— Necrotizing soft-tissue infection.

— Severe DKA/HHS with hemodynamic instability.

— Respiratory failure or multi-organ dysfunction.

— Podiatry/foot and ankle surgery — debridement, offloading, biomechanics.

— Vascular surgery — any abnormal pulse exam, ABI/TBI/TcPO₂ abnormality, non-healing wound.

— Infectious disease — osteomyelitis, MDR organisms, prolonged IV therapy.

— Endocrinology — uncontrolled hyperglycemia, brittle diabetes, insulin pump issues.

— Plastic surgery — soft-tissue reconstruction, free flaps.

— Wound care nursing — dressings, NPWT, education.

— Nutrition, social work, behavioral health, PT/OT — round out the team.

CCS pearl: For a febrile diabetic with a foul-smelling foot ulcer and soft-tissue gas on X-ray, the correct CCS sequence is: IV access × 2, fluids, broad-spectrum antibiotics (vanc + pip-tazo + clindamycin), STAT surgical consult, NPO, type and screen, blood cultures, lactate, ICU admission — imaging should not delay OR transfer.

Admit to hospital for:

ICU admission criteria:

Consultations to mobilize early (the "diabetic foot team"):

Evidence: Multidisciplinary diabetic foot teams reduce major amputation by ~50%.

Key Differentials — Same-Category (Ulcerative) Lesions

— Location: medial gaiter area (above medial malleolus).

— Features: shallow, irregular borders, wet/exudative, hemosiderin staining, lipodermatosclerosis, varicosities, ankle edema.

— Pulses preserved; ABI normal.

— Management: compression therapy (after ruling out arterial insufficiency).

— Location: toe tips, lateral foot, heel.

— Features: dry, punched-out, pale base, painful (unless masked by neuropathy), atrophic skin, absent pulses.

— Management: revascularization is the cornerstone.

— Location: heel, lateral malleolus in bed-bound patients.

— Features: staged I–IV, often in immobilized/elderly; key intervention is pressure offloading and turning schedule.

— Rapidly expanding, violaceous undermined border, very painful, associated with IBD, RA, hematologic disease.

— Pathergy (worsens with debridement) — biopsy edge, not center; treat with systemic steroids/immunosuppressants, NOT debridement.

— Punched-out, palpable purpura, livedo, systemic features; biopsy shows leukocytoclastic or larger-vessel vasculitis.

— ESRD or hyperparathyroidism, livedo racemosa, extremely painful necrotic ulcers on adipose-rich areas (thighs, abdomen) or distal extremities; sodium thiosulfate, control Ca/PO₄.

— Chronic non-healing ulcer (often >3 months at one site) with rolled, heaped edges → biopsy to rule out squamous cell carcinoma.

Board pearl: Any ulcer that fails to show ≥50% area reduction at 4 weeks despite optimal care needs reassessment for missed osteomyelitis, ischemia, pyoderma gangrenosum, or malignancy — biopsy is appropriate.

Venous stasis ulcer:

Arterial (ischemic) ulcer:

Pressure (decubitus) ulcer:

Pyoderma gangrenosum:

Vasculitic ulcer:

Calciphylaxis:

Malignant ulcer (Marjolin):

Key Differentials — Other-Category Causes of the Painful/Swollen Diabetic Foot

— Warm, red, swollen foot without an ulcer; preserved pulses; often misdiagnosed as cellulitis. Temperature differential >2°C vs contralateral foot is a clue. Offload immediately.

— Diffuse erythema with sharp borders, warmth, systemic signs; responds to antibiotics. Bilateral lower-extremity "cellulitis" is usually stasis dermatitis, not infection.

— Unilateral calf > foot swelling, Homan sign unreliable, elevated D-dimer, duplex ultrasound diagnostic. Diabetes confers higher risk.

— Acute monoarthritis, often 1st MTP (podagra), exquisitely painful, erythematous; joint aspiration (negatively birefringent needle-shaped crystals for gout). Diabetics are at increased risk; can coexist with infection — aspirate to differentiate.

— Single hot joint, painful with passive ROM, fever, elevated synovial WBC >50,000 with neutrophil predominance; emergent washout.

— Neuropathy masks pain; plain film may be initially negative — repeat in 2 weeks or get MRI if suspicion persists.

— Episodic red, hot, burning feet; relieved by cooling; associated with myeloproliferative disorders.

— Painful diabetic neuropathy treated with duloxetine, pregabalin, gabapentin, or TCAs; no role for opioids first-line.

Key distinction: Charcot vs cellulitis vs DVT in the warm, swollen diabetic foot — elevate the leg for 5–10 minutes: Charcot redness fades, cellulitis often persists. Combine with ulcer status, pulses, temperature differential, and duplex/MRI as needed.

Acute Charcot neuroarthropathy:

Cellulitis (without ulcer):

DVT:

Gout / pseudogout:

Septic arthritis:

Stress fracture / occult trauma:

Erythromelalgia:

Peripheral neuropathic pain syndromes (mimicking ulcer-associated pain):

Insect bite, contact dermatitis, tinea pedis with secondary infection — often missed in routine exams.

Secondary Prevention, Discharge Medications, and Long-Term Plan

— Custom therapeutic footwear and accommodative insoles — Medicare covers annually; reduces re-ulceration by ~50%.

— Daily self-inspection (or by caregiver) — mirror, hand check; report changes within 24 hours.

— Podiatry follow-up every 1–3 months for callus debridement and nail care.

— Avoid barefoot walking, hot water (test temperature with elbow or thermometer), home bathroom surgery on calluses/nails.

— Individualized A1c target (<7% if young/healthy, <8% if comorbid, <8.5% if frail).

— Metformin baseline; add SGLT2 inhibitor (cardio/renal benefit; caution with foot ulcer history — early CANVAS signal of amputation with canagliflozin, weigh risk/benefit) or GLP-1 RA for weight and cardiovascular benefit.

— Insulin as needed; CGM in selected patients.

— High-intensity statin (atorvastatin 40–80, rosuvastatin 20–40) — LDL goal <70 mg/dL (often <55 in established ASCVD).

— ACE inhibitor or ARB if HTN, albuminuria, or CKD.

— Antiplatelet (aspirin 81 mg) for established ASCVD; add rivaroxaban 2.5 mg BID in symptomatic PAD post-revascularization (COMPASS/VOYAGER PAD).

— Smoking cessation — counsel at every visit, varenicline or nicotine replacement.

Step 3 management: At discharge after a healed diabetic foot ulcer, order: custom diabetic shoes referral, podiatry follow-up in 1 month, A1c in 3 months, statin + ACEi + aspirin + SGLT2/GLP-1, smoking cessation, and document the patient self-inspection plan.

Wound recurrence prevention (the highest-yield intervention in healed ulcer patients):

Glycemic control:

Cardiovascular risk reduction (most diabetics with foot disease have systemic atherosclerosis):

Vaccinations: annual influenza, pneumococcal series, COVID-19 boosters, HBV (CDC recommends for unvaccinated adults with diabetes), shingles (≥50), tetanus current.

Annual diabetes care bundle: dilated eye exam, urine albumin/Cr ratio, lipid panel, foot exam, dental care, depression screen.

Follow-Up, Monitoring Parameters, and Counseling

— Weekly while healing — measure (length × width × depth), photograph, debride, reassess offloading, dressing change instructions.

— At 4 weeks: ≥50% area reduction expected; if not met, escalate (re-image, reassess perfusion, biopsy, change therapy).

— At 12 weeks: ulcer should be healed or substantially smaller; if not, ID/vascular/plastics input.

— Podiatry every 1–3 months for life in high-risk patients (prior ulcer/amputation, Charcot, ESRD).

— Primary care diabetic foot exam at every visit, comprehensive exam annually.

— Antibiotics: baseline and weekly CBC, BMP, LFTs on prolonged courses; vancomycin trough/AUC, linezolid CBC weekly (thrombocytopenia), fluoroquinolone — QT, glucose, tendinopathy.

— Glycemic: A1c every 3 months until at goal, then every 6 months.

— CKD: eGFR and UACR annually; adjust meds.

— Lipids/BP: at least annually; titrate to target.

— "Inspect your feet daily — top, bottom, between toes — and call us for any new redness, blister, drainage, or change in shape."

— "Never walk barefoot, even at home."

— "Buy shoes in the afternoon when feet are largest; break in slowly."

— "Cut nails straight across; let a podiatrist handle calluses."

— "Check water temperature with your elbow."

— Gait retraining after amputation, prosthesis fitting, balance training to reduce falls.

— Behavioral support — depression screening (PHQ-9) at each visit; treat aggressively (worsens adherence and healing).

Board pearl: The most predictive single follow-up data point is percent wound area reduction at 4 weeks — failure to meet 50% reduction should trigger formal reassessment, not just "more time and same plan."

Active ulcer follow-up cadence:

Post-healing surveillance ("remission"):

Monitoring labs on therapy:

Patient counseling pearls:

Rehab and OT/PT:

Ethical, Legal, and Patient Safety Considerations

— Must include limb salvage alternatives, expected functional outcome, prosthesis options, mortality risk, and the realistic chance of contralateral amputation.

— Document decision-making capacity explicitly — depression, delirium from sepsis, or pain may impair capacity; involve psychiatry or surrogate decision-makers if in doubt.

— Surrogate decision-making hierarchy varies by state; know your jurisdiction.

— Some patients (elderly, frail, non-ambulatory) may rationally choose primary amputation over a high-risk bypass with low chance of meaningful limb function — respect autonomy and document the conversation.

— Palliative care consultation is appropriate when wound burden is end-of-life or quality-of-life dominated.

— Discharge after foot infection is a high-risk handoff. Concrete safeguards:

— Confirmed outpatient antibiotic plan with specific stop date and adverse effect monitoring.

— Podiatry/vascular follow-up scheduled before discharge, not just recommended.

— Dressing supplies and home health arranged.

— Glycemic regimen reconciled (steroids during inpatient may have driven insulin needs; reassess at discharge).

— Caregiver present at discharge teaching.

— "Wrong-site" surgery prevention: mark the operative foot/toe, time-out per Universal Protocol.

— Heel pressure ulcer prevention in inpatients: float heels off the bed, document daily skin checks — these are reportable hospital-acquired conditions and may affect reimbursement.

— Medication safety: renal-dose all antibiotics; flag QT-prolonging combinations; check vaccines.

Step 3 management: Before discharging a diabetic with a recently debrided foot ulcer on IV antibiotics via PICC, confirm: home infusion arranged, weekly labs scheduled, podiatry and ID appointments booked, dressing supplies delivered, and caregiver teach-back completed — missing any of these is a board-favorite "preventable readmission" stem.

Informed consent for amputation:

Shared decision-making in CLTI:

Transition-of-care risks (Step 3 favorite):

Patient safety:

Mandatory and ethical reporting: Elder abuse/neglect with untreated wounds and poor hygiene may trigger APS reporting; document and report per state law.

Health equity: Black, Hispanic, and Native American patients have 2–4× higher amputation rates — address access, insurance, language, and structural barriers.

High-Yield Associations and Rapid-Fire Clinical Facts

— Lifetime ulcer risk in diabetes: ~25%.

— Ulcers precede 85% of diabetes-related amputations.

— Major amputation 5-year mortality: ~50%.

— Recurrence: 40% at 1 year, 65% at 5 years.

— ABI: ≤0.90 PAD, <0.40 severe; >1.30 noncompressible.

— TBI: <0.70 abnormal; TcPO₂ <30 mm Hg = poor healing.

— ESR >70 mm/hr → suspect osteomyelitis.

— Probe-to-bone: PPV ~60%, NPV ~90%.

— Wound area reduction goal: ≥50% at 4 weeks.

— Acute/mild: Staph aureus, Streptococcus.

— Chronic/previously treated: polymicrobial — GPCs + GNRs + anaerobes.

— Macerated/water exposure: Pseudomonas.

— Necrotic, foul, gas: anaerobes (Bacteroides, Clostridium), mixed.

— Puncture wound through sneaker: Pseudomonas osteomyelitis.

— Plain film: cortical destruction, periosteal reaction, soft-tissue gas, foreign body, Charcot deformity (rocker-bottom).

— MRI: bone marrow edema = osteomyelitis vs Charcot (location: forefoot favors infection; midfoot favors Charcot).

— Canagliflozin: early amputation signal — caution in high-risk feet.

— Fluoroquinolones: tendon rupture, especially with steroids; aortic aneurysm risk.

— Linezolid >2 weeks: thrombocytopenia, peripheral/optic neuropathy, serotonin syndrome.

— Vancomycin: nephrotoxicity, red-man syndrome (infusion rate).

Board pearl: Puncture wound through a sneaker → Pseudomonas aeruginosa osteomyelitis is a perennial Step 3 buzz association; cover with ciprofloxacin or antipseudomonal beta-lactam.

Numbers to memorize:

Pathogens by scenario:

Imaging tells:

Guideline-name drops: IDSA/IWGDF diabetic foot infection guidelines (2023), ADA Standards of Care annual screening, BEST-CLI trial (bypass with great saphenous vein for CLTI in suitable candidates).

Drug-foot pearls:

Coverage trivia: Medicare's Therapeutic Shoe Bill covers one pair of custom shoes and three pairs of inserts annually for qualifying diabetics.

Board Question Stem Patterns

— 58-yo with type 2 DM, A1c 9.2%, painless 1.5-cm ulcer at first metatarsal head, surrounded by callus, palpable pulses, no erythema.

— Answer: debridement, total contact cast, glycemic optimization, no antibiotics.

— Chronic ulcer for 6 weeks, ESR 95, probe touches bone, plain film shows cortical erosion.

— Answer: MRI ± bone biopsy; 6-week culture-directed antibiotics ± surgical debridement.

— Diabetic with painless warm swollen erythematous foot, no ulcer, WBC normal, plain film: midfoot dislocation.

— Answer: acute Charcot → offload with total contact cast; do not give antibiotics.

— Fever, hypotension, foul drainage, soft-tissue gas on X-ray.

— Answer: IV fluids, blood cultures, lactate, vancomycin + pip-tazo ± clindamycin, urgent surgical debridement, admit ICU.

— Foot ulcer not healing, ABI 1.4.

— Answer: noncompressible vessels — order toe-brachial index or TcPO₂, not "vessels are fine."

— Ulcer area unchanged after 4 weeks of standard care.

— Answer: reassess perfusion (re-image vasculature), rule out osteomyelitis (MRI), consider biopsy for malignancy or pyoderma gangrenosum, audit offloading adherence.

— Patient ready for discharge after foot infection.

— Answer: podiatry + ID + vascular follow-up scheduled, home health, dressings, antibiotic plan with stop date, glycemic regimen, custom shoes referral, smoking cessation, statin/ACEi/aspirin.

— Answer: Pseudomonas osteomyelitis — ciprofloxacin or antipseudomonal coverage; consider surgical exploration.

Key distinction: When the stem describes a chronic non-healing ulcer with rolled heaped edges over months to years, think Marjolin ulcer (SCC) — the right answer is biopsy, not another course of antibiotics.

Stem 1 — "The painless plantar ulcer":

Stem 2 — "Probe-to-bone":

Stem 3 — "The warm red foot without an ulcer":

Stem 4 — "Severe infection / sepsis":

Stem 5 — "ABI = 1.4 in CKD":

Stem 6 — "Failure to heal at 4 weeks":

Stem 7 — "Discharge planning":

Stem 8 — "Puncture through sneaker":

One-Line Recap

Bottom line: Diabetic foot ulcers are the predictable, preventable, and recurrent endpoint of neuropathy, ischemia, and unrecognized trauma — and successful Step 3-level care requires combining structured risk-based screening, aggressive offloading, source control of infection, vascular assessment with revascularization when indicated, glycemic and cardiovascular risk reduction, and lifelong multidisciplinary follow-up framed as remission rather than cure.

Board pearl: When in doubt on a Step 3 diabetic foot stem, the right answer almost always involves offloading, addressing perfusion, and arranging structured multidisciplinary follow-up — rarely "another antibiotic."

Screen and stratify every visit: monofilament + vibration + pulses + inspection; categorize IWGDF 0–3 to set follow-up cadence; document loss of protective sensation when present.

Manage active ulcers with the 5 S's: Sharp debridement, Sepsis control (treat infection only when clinically infected, IDSA-graded antibiotics with culture-guided de-escalation), Supply (ABI/TBI/TcPO₂ then revascularize if abnormal or failing), Shoes (total contact cast = gold standard for plantar neuropathic ulcers), Sugars (individualized A1c, avoid hypoglycemia); benchmark ≥50% area reduction at 4 weeks or reassess.

Don't miss the masqueraders: acute Charcot (warm red painless foot without ulcer — offload, don't antibiotic), osteomyelitis (probe-to-bone + ESR >70 → MRI ± bone biopsy → 6-week culture-directed therapy), pyoderma gangrenosum (don't debride), Marjolin ulcer (biopsy chronic non-healing wounds), and CLTI (urgent vascular referral).

Secondary prevention saves limbs and lives: custom therapeutic footwear, podiatry every 1–3 months, daily self-inspection, smoking cessation, statin + ACEi/ARB + antiplatelet + SGLT2/GLP-1, vaccinations, depression screening, and engineered transitions of care with explicit follow-up before discharge.